Loading
companiesCompany
Indapta Therapeutics
Indapta Therapeutics, of Houston, makes IDP-023, an off-the-shelf natural killer cell therapy from donor g-NK cells, a subset that lacks the FcR gamma chain, and tests it alongside antibody drugs in myeloma and non-Hodgkin lymphoma and in progressive multiple sclerosis. The FDA granted Fast Track status in 2024, and efficacy data are still early.
Overview
Indapta Therapeutics is developing IDP-023, a proprietary, off-the-shelf allogeneic FcR gamma-deficient natural killer (g-NK) cell therapy for cancer and autoimmune disease. According to release titles on the company site, the first patients were treated with IDP-023 in January 2024, the FDA granted Fast Track designation for non-Hodgkin lymphoma and myeloma in February 2024, the company received a $4.5 million CPRIT award in May 2024, an IND for progressive multiple sclerosis was cleared in August 2024, a clinical study collaboration with Sanofi in multiple myeloma was announced in December 2024, and clinical activity in relapsed or refractory multiple myeloma was presented in November 2025. SEC Form D filings list the company in Houston, Texas, with about $33.6 million of equity sold in early 2022 and about $50.8 million sold in an offering that began in September 2025.
Headquarters
Houston, TX, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
top- The user's hint says San Francisco; Form D filings give Houston, TX. Programme milestones are taken from press-release titles linked on the homepage (the Business Wire pages themselves returned 403). The g-NK product is not CAR-engineered; 'car-nk-macrophage' is the closest available id. The December 2024 $22.5 million financing release could not be fetched.
Similar pages
- CompanyONK Therapeutics
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- PersonKatayoun Rezvani
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
- TechnologyNK cell therapy and CAR-NK
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
- CompanyPoseida Therapeutics
Shares Allogeneic (off-the-shelf) cell therapy, Multiple myeloma, Diffuse large B-cell lymphoma.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
- TechnologyAllogeneic donor and iPSC master cell banks
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- IdeaQualify one iPSC master cell bank once for many off-the-shelf cell products
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- CompanyFate Therapeutics
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.